Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Summary

To evaluate the efficacy of NYX-2925 versus placebo for the treatment of fibromyalgia.

Timeline

Start

2019-11-12

Primary completion

2022-06-16

Completion

2022-06-16

Outcome

Missed primary endpoint

registry analysis (superiority test); NYX-2925 50 mg vs Placebo; p = 0.539; t-test, 2 sided NCT04147858 ↗

registry analysis (superiority test); NYX-2925 100 mg vs Placebo; p = 0.425; t-test, 2 sided NCT04147858 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NYX-2925	Small molecule	50 mg	Oral
Subject	NYX-2925	Small molecule	100 mg	Oral

Indications